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Background: In Australia, cancer survival is significantly lower in non-metropolitan compared to metropolitan areas. Our objective was to evaluate the evidence on geographical
variations in the clinical management and treatment of colorectal cancer (CRC).
Methods: A systematic review of published and gray literature was conducted. Five
databases (CINAHL, PubMed, Embase, ProQuest, and Informit) were searched for
articles published in English from 1990 to 2018. Studies were included if they assessed
differences in clinical management according to geographical location; focused on CRC
patients; and were conducted in Australia. Included studies were critically appraised
using a modified Newcastle–Ottawa Scale. PRISMA systematic review reporting methods were applied.
Results: 17 articles met inclusion criteria. All were of high (53%) or moderate (47%)
quality. The evidence available may suggest that patients in non-metropolitan areas are
more likely to experience delays in surgery and are less likely to receive chemotherapy
for stage III colon cancer and adjuvant radiotherapy for rectal cancer.
Conclusion: The present review found limited information on clinical management
across geographic regions in Australia and the synthesis highlights significant issues
both for data collection and reporting at the population level, and for future research in
the area of geographic variation. Where geographical disparities exist, these may be due
to a combination of patient and system factors reflective of location. It is recommended
that population-level data regarding clinical management of CRC be routinely collected
to better understand geographical variations and inform future guidelines and policy.
Keywords: colorectal cancer, rural health, health disparity, cancer treatment, systematic review
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INTRODUCTION

METHODS

Australia and New Zealand have the highest incidence rates of
colorectal cancer (CRC) in the world, and it is the second leading
cause of cancer death in Australia (1, 2). Around 80 Australians
die each week from CRC; however, if detected early it can be
treated successfully (3). The Australian National Health and
Medical Research Council and Cancer Australia have developed
evidence-based guidelines for optimal care in the clinical management of CRC (4, 5). These guidelines recommend that patients
should receive site- and stage-specific care including preoperative
assessment, surgery, and adjuvant therapy where appropriate.
Specifically, primary surgical resection is recommended for stage
I to III CRC, except for low-grade stage I where local excision is
appropriate; adjuvant chemotherapy for all node-positive colon
cancers; adjuvant preoperative or postoperative radiotherapy
for high risk rectal cancers; and chemotherapy for metastatic
CRC. The guidelines also recommend less than 30 days between
diagnosis and surgery, and receipt of treatment in specialist
cancer centers or from specialist surgeons (5). To date, it is
unclear whether these guidelines are adhered to uniformly across
Australia.
In Australia, survival from CRC differs according to geographical location, with mortality rates higher in regional and
remote areas compared to major cities (1, 6–8). Geographical
variations in access to recommended treatments may contribute
to the noted disparities in survival and other outcomes. Only 78
sites across Australia deliver radiotherapy treatment (42% private
providers), with the majority of these located in capital cities or
major regional centers (9). An analysis of available radiotherapy
services in Australia in 2009 found that only 38% of cancer patients
for whom radiotherapy was the appropriate treatment could be
treated within the current service capacity, with lower percentages expected in regional and rural Australia (10). Geographical
differences in surgery and chemotherapy also exist as there are
reported gaps in the percentage of non-metropolitan hospitals
with medical oncologists or specialist surgeons, and reports of
administration of chemotherapy by staff without oncology training (11, 12).
Residents in metropolitan areas have increased access to services, and access to hospitals and surgeons with higher caseloads;
factors known to be associated with better clinical outcomes (13,
14). However, few population-level datasets in Australia include
comprehensive treatment data or clinical management information (15), and to date, there has been no aggregation and synthesis
of available data. This evidence gap hampers our understanding
of disparities in clinical care and how these might influence cancer outcomes. A preliminary survey of the literature regarding
geographic disparities in outcomes for patients diagnosed with
CRC highlighted a lack of clear, consistent findings and identified
a need for a more in-depth examination of differences in clinical
management (8). Thus, the primary aim of this systematic review
was to understand the nature of geographical variations in the
clinical management of CRC (including surgery, chemotherapy,
and radiotherapy) in Australia, incorporating clinical reports as
well as peer-reviewed literature.

The review methodology was planned and carried out following the PRISMA statement for the conduct and reporting of
systematic reviews (16). The review protocol was registered
with PROSPERO; registration number CRD42016042666
(https://www.crd.york.ac.uk/PROSPERO/display_record.
asp?ID=CRD42016042666).
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Eligibility Criteria

Studies were included if the data were from cohorts of
Australian individuals with CRC; reflected outcomes pertaining to clinical management; and compared non-metropolitan
vs metropolitan patients. Qualitative studies, review articles,
editorials, books, commentaries, and conference abstracts were
excluded.

Search Strategy

PubMed, CINAHL, Embase, ProQuest, and Informit databases
were searched for articles published in English from 1990 to
26th February 2018. Search strings included terms relating to
“colorectal cancer” or “bowel cancer,” “clinical management,”
“treatment,” “chemotherapy,” “radiotherapy,” or “surgery.” Terms
relating to geographical disparities included “metropolitan,”
“urban,” “rural,” “remote” or “regional,” and “Australia.”
Gray literature searches were conducted through targeted
Internet searches of state and federal government health websites,
non-government cancer association (e.g., state Cancer Council
groups) websites, web search engines (Google), and manual hand
searching of reference lists of included articles.

Screening and Data Extraction

After removing duplicates, titles and abstracts were independently screened by two reviewers for relevance according to the
selection criteria. Full text versions of potentially eligible articles
were then assessed for inclusion by two independent reviewers.
Reviewer discrepancies were discussed and resolved within the
project team where necessary.
Criteria for data extraction were determined prior to review.
Summary data for each study included design, data sources,
participants, geographic classification system, dates of data collection, clinical management details, and key trends. Extracted
data were synthesized descriptively.

Quality Assessment

The methodological quality of each paper meeting the inclusion criteria was assessed using a tool previously developed for
research in breast cancer, based on the Newcastle–Ottawa Scale
for assessing quality in non-randomized studies (17, 18). Studies
were scored according to the extent that they met each of nine
criteria ranging from high risk of bias (score of 0), intermediate
risk of bias (score of 1), and low risk of bias (score of 2). Criteria
scores were then summed and categorized as “high” (14–18),
“moderate” (9–13), or “low” (<9) quality. Study quality appraisal
was carried out by two authors, and a third author resolved disagreements between the initial two reviewing authors.
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RESULTS

variations in aspects of surgical management, although methodologies varied greatly. A retrospective data linkage study found
that patients residing in remote areas of Western Australia were
more likely to receive surgery compared to patients residing in
any other area (25). However, when location of hospital was
considered, patients were more likely to receive surgery when
their first admission was to a metropolitan facility rather than
a rural hospital (25, 28). A Queensland audit report suggested
that it was more likely for patients residing in metropolitan areas
to have surgery less than 30 days after diagnosis, compared to
patients in outer regional and remote areas (31). A retrospective
cohort analysis from New South Wales reported that among
rectal cancer patients there was a longer delay until surgery for
individuals living in rural areas, but this was not the case for colon
cancer patients (24). A clinicians report from NSW examined
preoperative investigations, and reported that patients residing
in highly accessible areas were significantly more likely to have
had recommended tests such as colonoscopy, sigmoidoscopy,
and scans for distant metastases compared to those living in less
accessible areas (13).

The search strategy yielded 690 records in total. After removal
of duplicates, 681 records were screened by title and abstract. Of
those, 153 full-text articles were potentially relevant and assessed
for eligibility. Following assessment, 17 studies were included in
the final review, comprising 12 peer-reviewed articles and 5 gray
literature reports (Figure 1). Because of the diverse nature of the
study designs, a quantitative synthesis was not possible and a
narrative review of individual studies is provided.
Table 1 presents the key characteristics of all 17 included studies. Eight studies (47%) were of moderate quality, including all
five gray literature reports. All other included studies (53%) were
high quality indicating they have samples that were representative of the population, variables were collected through secure
records, important confounders were controlled for, and statistical methods were appropriate and well presented.

Main Findings
Surgery

Eight studies reported on surgical management. Three studies
reported no significant variation in rates of surgical treatment
according to place of residence, for all stage cancers (15) or
metastatic disease (27, 32). Five studies reported geographical

Chemotherapy

Eight studies examined chemotherapy management. Three studies indicated that chemotherapy for stage III colon cancer was less

Figure 1 | PRISMA flow diagram of included studies.
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Quasi-experimental design
using retrospective chart
audit, and hospital data from
Mt Isa hospital and Townsville
Cancer Centre (TCC)

Cross-sectional cohort study
National Colorectal Cancer
Care Survey

Chan
et al. (22)

Clinical
Governance
Unit (23)

Population-based data
linkage study
South Australian Cancer
Registry, hospital data,
radiotherapy databases,
hospital-based cancer
registries

Beckmann
et al. (15)

Population-based data
South Australian Cancer
Registry, hospital data, and
radiotherapy databases

Population-based crosssectional cohort study
New South Wales colorectal
cancer care survey

Armstrong
et al. (13, 19,
20)

Beckmann
et al. (21)

Design and sources

Study

Table 1 | Characteristics of included studies.

ARIA

ARIA+ (combined
remote/very remote
category)

CRC patients (N = 3,095
surgery, N = 778 chemo,
N = 238 radiotherapy)

Residents aged 50 to
79 years with CRC
N = 4,641

Clinicians treating CRC
patients, including
surgeons, medical and
radiation oncologists
(N = 2,669)

Patients who received
chemotherapy at TCC
and Mt Isa (N = 206).
Mt Isa patients received
chemotherapy through a
tele-oncology model
Patients postcode
(capital city, urban,
or rural)

ASGC classification
(Mt Isa = Remote,
Townsville = Outer
Regional)

ARIA (collapsed into
Residents aged
metropolitan and
50–79 years diagnosed
with CRC who underwent non-metropolitan)
surgical resection
(N = 3,887; N = 3,940
resections)

Rural/urban
classification

Population

No significant differences in risk of
post-procedural complications, or
risk of readmission were observed in
relation to place of residence

Prevalence ratio of variations in
receipt of surgical treatment
Inner urban = 1.00 reference outer
urban PR = 0.98
Rural PR = 0.99
Remote PR = 1.01

Percentage of preoperative
investigations by location of
residence
Highly accessible = 84%,
accessible = 14%
Moderately accessible = 2%
Remote/very remote areas = 1%

Key findings relating to surgery

There were no significant differences
between the Mt Isa and Townsville patients
in mean number of treatment cycles, dose
intensities, proportions of side effects,
and hospital admissions. There were no
toxicity-related deaths in either group
Preoperative
radiotherapy was
more likely to be
received by patients
in capital city (68%)
and urban locations
(83%) than rural
locations (44%),
p = 0.004

Prevalence ratio of
High
variations in receipt of
radiotherapy
Inner urban
PR = 1.00 reference
Outer urban
PR = 0.87
Rural PR = 0.87
Remote PR = 1.13
Prevalence ratio of variations in receipt of
chemotherapy for stage III CRC
Inner urban = 1.00 reference Outer urban
PR = 1.03, p = 0.63
Rural PR = 0.87, p = 0.046
Remote PR = 0.86, p = 0.14

(Continued)

Moderate

High

High

Moderate
Patients in highly
accessible areas
had a lower use
of radiotherapy
(30%) compared to
patients in accessible
(36%), moderately
accessible (35%) and
remote/very remote
areas (38%)

Quality
rating

Recommended chemotherapy treatment
was most likely to be received by patients
in “highly accessible” or “accessible”
areas (68–69%) compared to “moderately
accessible to very remote” patients (43%)

Key findings relating to chemotherapy Key findings
relating to
radiotherapy

Crawford-Williams et al.
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Retrospective cohort study
South Australian Clinical
Registry for Metastatic
Colorectal Cancer

Hocking
et al. (27)

Retrospective data linkage
study
West Australian Data Linkage
System

Hall et al. (25)

Population-based cohort
study
ECO database (extension of
Victorian Cancer Registry,
which includes clinical and
treatment information)

Retrospective cohort analysis
of linked data
New South Wales central
cancer registry; 45 and Up
study; admitted patient data
collection; and Medicare
claims

Goldsbury
et al. (24)

Henry
et al. (26)

Design and sources

TABLE 1 | Continued

Study

5
Patients with metastatic
CRC
(N = 2,289)

Residents in the Barwon
South Western Region
(Victoria) with a cancer
diagnosis (N = 1,778 for
all cancer types)

Postcodes within
state capital were
“city,” remaining
postcodes were
“rural”

Distance from
Geelong city (km)

ARIA

No significant differences in
colorectal surgery (51.5% city vs
55.3% rural, p = 0.11), liver surgery
(13.7 vs 11.5%, p = 0.17), or lung
surgery (3.2 vs 2.1%, p = 0.10)

Patients in remote areas most
likely to receive surgery (OR 1.21),
compared to very remote (OR 0.70)
accessible (OR 1.08), moderately
accessible (OR 1.01), and highly
accessible (OR 1.00 reference)

Hazard ratio of variation in rectal
cancer time to surgery: Rural
HR = 0.47; other urban HR = 1.55;
metro HR = ref 1.00
Hazard ratio of variation in colon
cancer time to surgery: rural
HR = 1.21; other urban HR = 1.19;
metro HR = ref 1.00
Surgery in a specialist cancer center
was more frequent among those
living in metro areas (HR = 1.00)
compared to other urban areas
(HR = 0.27) or rural areas
(HR = 0.14)

Place of residence
at diagnosis
(metropolitan, other
urban, or rural)

Residents participating
in the 45 and Up study
diagnosed with CRC
who had a colonoscopy
before diagnosis and
surgery after diagnosis
(N = 407)

Residents with diagnosis
of invasive primary CRC
N = 14,587

Key findings relating to surgery

Rural/urban
classification

Population

Equivalent rates of chemotherapy between
metropolitan and rural patients across
each line of treatment (56.0 vs 58.3%,
respectively, p = 0.32). A higher proportion
of city patients received combination
chemotherapy in the first-line setting (67.4
vs 59.9%; p = 0.01). When an oxaliplatin
combination was prescribed, oral
capecitabine was used more frequently in
rural patients (22.9 vs 8.4%; p < 0.001)

High

High

Quality
rating

(Continued)

Moderate

Moderate
Lower radiotherapy
utilization was
observed for patients
living in rural areas
compared with those
living in Geelong for
rectal cancer (32.8
vs 44.7%, p = 0.11).
Time from diagnosis
to radiotherapy was
not significantly
different for the
different geographical
regions

Key findings relating to chemotherapy Key findings
relating to
radiotherapy

Crawford-Williams et al.
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Retrospective populationbased audit
Queensland Oncology
Repository

Queensland
Government
(31)

Population-based cohort
study
Pathology records from four
West Australian hospitals

Morris
et al. (29)

Retrospective clinical chart
audit
Hospital records (Townsville
Cancer Center)

Linked population-based
cohort study
New South Wales cancer
registry; admitted patients
data collection; births, deaths
and marriages

Jorgensen
et al. (28)

Pathmanathan
et al. (30)

Design and sources

Study

TABLE 1 | Continued

Queensland patients
diagnosed with colon
(N = 1,537) and rectal
(N = 656) cancer who
had a major resection

ASGC

Colon cancer % days from
diagnosis to surgery ≤30
Major city = 77%; inner
regional = 74%; outer
regional = 70%; remote = 70%
Rectal cancer % days from
diagnosis to surgery ≤30
Major city = 44%; inner
regional = 34%; outer
regional = 35%; remote = 21%

A similar number of patients received
XELOX as a second-line treatment in urban
(n = 10; 40%) and rural (n = 8; 31%) areas
with a similar number of cycles (urban
n = 49; 31% vs rural n = 37; 24%). No
differences in dose intensities were
apparent

RRMA 3 ≥3
classified as rural,
RRMA 2 (Townsville)
classified as urban

Patients from Townsville
or North West
Queensland districts
aged > 18 years
diagnosed with colorectal
cancer (N = 51)

Rates of chemotherapy initiation not
different between rural hospitals (33.3%)
and metropolitan district, private and
teaching hospitals (21.1, 47.1, and 31.8%)
Rates of chemotherapy completion not
different between metropolitan district
hospitals and rural hospitals (48.4 vs
45.2%, respectively), but higher in
metropolitan private and teaching hospitals
(73.3 and 69.3%)

One rural hospital vs
three metropolitan
hospitals (teaching,
private, and district)

Quality
rating

(Continued)

Moderate

Moderate

High

Approximately 28% of High
the total variability in
radiotherapy receipt
was attributable to
hospitals (ICC = 0.28),
2% was attributable
to surgeons and the
remaining 70% to
patient characteristics

Key findings relating to chemotherapy Key findings
relating to
radiotherapy

Stage III colon cancer
patients
(N = 1,312)

Key findings relating to surgery

The majority of the variability in receipt of
chemotherapy was attributable to patient
characteristics (≈84%), with hospital of
surgery accounting for the remaining
variability (ICC = 0.16)

Rural/urban
classification

ARIA (remoteness
Individuals with lymph
areas); surgeon, and
node-positive colon
hospital caseload
cancer (N = 580) and
high-risk rectal cancer
(N = 498) who underwent
surgery following
diagnosis

Population

Crawford-Williams et al.
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ARIA = Accessibility/Remoteness Index of Australia; ASGC = Australian Standard Geographical Classification; CRC = colorectal cancer; HR = hazard ratio; OR = odds ratio; PR = prevalence ratio; RRMA = Rural, Remote,
Metropolitan Area.

Patients offered recommended adjuvant
chemotherapy for colon cancer were
more likely to be treated in a metropolitan
hospital than rural hospital (OR = 1.00 vs
OR = 0.56, p = 0.04)
Hospital location
(metropolitan or
rural)
Prospective audit
New South Wales Central
Cancer Registry
Young
et al. (33)

NSW patients newly
diagnosed with CRC
(N = 3,095)

No significant differences between
major city, inner regional, outer
regional, and remote patients in
rates of lung surgery (1.8, 3.8, 1.1,
and 1.0% respectively; p = 0.104)
or liver surgery (13.0, 13.2, 13.6,
and 9.4%; p = 0.753)
ASGC
Retrospective cohort study
South Australian Clinical
Registry for Metastatic
Colorectal Cancer
Singla
et al. (32)

SA patients with
metastatic CRC
(N = 2,001)

Key findings relating to surgery
Rural/urban
classification
Population
Design and sources
Study

TABLE 1 | Continued
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likely to be received by patients residing in rural and remote areas
than metropolitan areas (15, 19, 33). One study found equivalent
rates of chemotherapy management between patients residing
in metropolitan and rural areas across each line of treatment,
although higher proportions of metropolitan patients received
combination chemotherapy in the first-line, and rural patients
had increased use of the oral prodrug capecitabine as first-line
treatment compared to metropolitan patients (27). In contrast,
two Queensland studies reported a similar number of chemotherapy cycles, regimen types, and dose-intensities used in both
rural and urban areas (22, 30). Two retrospective cohort studies
reported no geographical variation in receipt of chemotherapy
(28, 29).

High

High

Variation in CRC Treatment

Key findings relating to chemotherapy Key findings
relating to
radiotherapy

Quality
rating

Crawford-Williams et al.

Radiotherapy

Five studies examined radiotherapy management in rectal
cancer patients, with four reporting geographical disparities in
radiotherapy use. Specifically, one retrospective cohort study
reported lower utilization of radiotherapy in patients residing
in rural Victoria that was not explained by age; a pattern that
was more prominent in men than women (26). One cohort study
conducted in New South Wales reported variability in receipt of
radiotherapy as being attributable to location of hospital rather
than place of residence, with radiotherapy less likely to occur in
rural hospitals (28). In contrast, a New South Wales study of clinician reports suggested that patients residing in highly accessible
areas had lower use of radiotherapy than non-metropolitan areas;
however, this study had small numbers of rectal cancer patients
in moderately accessible and remote areas (20). One national
cross-sectional study reported that patients residing in rural areas
were less likely to receive preoperative radiotherapy for high-risk
rectal cancer although it is unclear whether these patterns are
indicative of patient characteristics, physician recommendations,
or health service accessibility (23). Only one retrospective datalinkage study found no differences in radiotherapy for stage II
and stage III rectal cancer according to location of residence in
South Australia (15).

DISCUSSION
The current review found inconsistent evidence relating to geographical disparities in clinical management of CRC in Australia.
While some studies showed no differences in treatment by location of residence, other studies reported that patients with CRC
in non-metropolitan areas of Australia are less likely to receive
optimal care. This was particularly true for studies where the
outcome was radiotherapy utilization. The evidence gathered in
this review highlights key issues with consistency in current data
collection and reporting regarding CRC treatments and clinical
management. In particular, the review highlights the importance
of recording location of treatment as well as location of residence;
gaps in data collection at a population-level; and large variability
in the methodologies used to investigate and report on geographical disparity. There is significant capacity for future research to
focus on these critical issues, as well as aspects missing from the
current literature such as treatment completion rates and reasons
for non-receipt of adjuvant therapies.
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Population level data collected in cancer registries internationally provides information on all cancers occurring in a certain
population (34). The type of data that cancer registries can provide
is varied, and while most provide information on incidence and
mortality, currently many registries, including those in Australia,
do not routinely collect data on stage at diagnosis or treatment
details (35). Hospital registries and other sources of clinical data
may have this information available, but it is generally limited
to a single institution or health service area. In clinical practice,
factors such as position of the tumor, lymph node invasion,
involved margins, as well as individual factors such as age, and
comorbidities influence CRC treatment decisions (4, 36), yet,
detailed clinical information is not available at the population
level. This significantly hampers research efforts attempting to
understand disparities in CRC management. The findings of the
current review emphasize a need for more comprehensive data
collection, particularly, in this era of electronic data. This might
involve the use of standardized reporting database software such
as electronic health records, whereby variables such as patients’
residence, hospital location, treatment type, tumor stage, and
comorbidities are recorded and able to be linked to cancer registry data. As the use of electronic health records and capacity for
data-linkage expands in Australia, and worldwide, these provide
a useful avenue for the collection of clinical management data
for CRC patients, with the ability to share information across
networks. The digital collection of cancer management data at
the population level could result in complex databases to be used
for a multitude of previously unanswered research questions (37).
Several studies reported that clinical management for CRC
was less optimal in non-metropolitan areas of Australia. For
instance, some studies reported that when non-metropolitan
patients underwent surgery for CRC, it was more likely to be
delayed and less likely to be preceded by preoperative investigations, radiotherapy for rectal cancer patients was underutilized
in non-metropolitan areas, and non-metropolitan patients with
stage III colon cancer were less likely to receive recommended
chemotherapy treatment. Despite potential differences in the
provision of chemotherapy across geographic locations, chemotherapy regimens were generally found to be similar across
metropolitan and non-metropolitan areas (22, 30). However,
one study indicated that oral chemotherapy was more likely
to be used for rural patients with metastatic disease (27). The
advantages of oral regimens over chemotherapy by infusion
include convenience, flexibility in location of administration,
and reduced toxicity-related hospitalization, which may be
of benefit to patients in non-metropolitan areas (38–40). For
these reasons, the use of innovative chemotherapy regimens is
a promising solution for overcoming the barrier of distance for
optimal CRC treatment.
Previous studies in Canada, the United States, and the United
Kingdom have also reported less optimal treatment provided
to non-metropolitan CRC patients (41–43), although again
evidence is mixed (41). A number of international studies have
reported that geographic variability in the treatment of CRC
may be reflective of the different population compositions in
regional areas, as well as hospital volume and service availability.
For instance, older patients, black patients, and patients of lower

Frontiers in Oncology | www.frontiersin.org

socioeconomic status (SES) were less likely to receive recommended treatments and more likely to have poorer outcomes
(43–47). As rural Australia is also characterized by populations
with lower education, lower SES, more advanced age, and higher
rates of Indigenous populations (12, 48), these sociodemographic
factors may explain many of the treatment differences reported
in the current review. If SES, ethnicity, and demographic characteristics are explanations for geographical disparity in cancer
treatment resulting in poorer cancer outcomes, there is an issue
of inequality that needs to be urgently addressed.
Studies that reported data comparing regional and metropolitan facilities, rather than basing geographic location on patient’s
home address, generally reported less optimal clinical management in non-metropolitan areas. This may suggest that there
are important differences in the quality of treatment for patients
receiving treatment in regional areas. If disparities in clinical
management of CRC are explained to some extent by accessibility
to appropriate services, then changes to health service delivery
may be an appropriate solution (11, 49). To date, increased use of
telehealth, the development of approved oral chemotherapy regimens, and the requirement for overseas trained health workers
to work in rural and regional areas are strategies implemented to
help overcome the challenge of distance (38, 50–52). The results
of this review suggest that planning for health service delivery
must continue to adapt and focus on overcoming barriers due
to distance. In particular, high priority areas are the recruitment and retention of specialist staff in non-metropolitan areas,
reduction of wait times, and tailoring services to individuals of
low SES, increased age, multiple comorbidities, and indigenous
populations.
Based on evidence presented above, it appears that clinical
management of CRC in non-metropolitan Australia may be less
than optimal; however, this may be due to a range of patient and
provider factors that correspond to geographic location. As evidence in this area is limited, one major contribution of the current
review is to motivate future research. Future studies will need to
collect more detailed data on clinical indicators, health professionals decision-making, and patient preferences to shed light
on potential variations in CRC treatment. To provide optimal
treatment equitably to patients with CRC, a better understanding
of the underlying causes of geographical variations in treatment
is required. Digital data collection tools provide an opportunity to
address this. Further investigation into the relative contribution
of patient, provider, and health system factors to geographical
disparities in clinical management is essential. Subsequently,
interventions designed to improve the quality of care can then be
directed at those patients most likely to benefit from them, such
as the provision of extra care from nurse navigators by assessing
and monitoring “at risk” patients. Additionally, health services
can use this information to adapt appropriately to suit the needs
of regional populations, for instance, through the extended use
of tele-oncology models of care, oral chemotherapy regimens, or
the development of outreach radiotherapy facilities to improve
quality of care for those living outside city centers. Not only is
this of relevance in Australia but also to countries with similar
geographic distributions and population characteristics such as
the US, Canada, and the UK.
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Limitations

is important to investigate differences in clinical management of
CRC across geographical locations, and in particular, the patient,
professional, or health service factors, which contribute to these
disparities. Causes for disparities in treatment are found not only
in the individual patients and their social environments but also
in the location and quality of the health-care system. It is recommended that population-level data regarding clinical management of CRC is routinely collected to improve health outcomes
and inform future guidelines and policy.

This review is limited by the small number of studies and the
use of inconsistent methodology across studies. The variation in
population samples, and use of different geographical classifications made direct comparisons between studies difficult. Above
all, research identifying geographical disparities in cancer outcomes is hindered by the lack of accurate patient and treatment
data at a population level. The use of digital systems to collect
and record clinical management information would enhance
understanding of variations in cancer outcomes and inform
policy and clinical guidelines. The reviewed studies emphasize
the need for better data collection and reporting, and highlight
the need for the use of data linkage to gather comprehensive
clinical management data.
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Conclusion

The present review provides specific information on clinical
management differences across geographic regions in Australia.
This synthesis of existing literature highlights significant issues
both for data collection and reporting at the population level, an
issue of relevance worldwide. Improvements in cancer outcomes
in regional areas will require enhanced capacity to accurately
track, and respond to, geographical disparities. Through the use
of electronic health records, data linkage and future research, it
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